Bioblast Pharma

Hope should not be rare

Latest Developments Archive

Latest Developments Archive

  • January 12, 2016
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Enhances Leadership Team

Appoints Industry Veteran, Robert W. Cook, as Chief Financial Officer

NEW HAVEN, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) — Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that it has appointed Robert (Bob) Cook to the position of Chief Financial Officer (CFO).  Mr. Cook will be a member of Bioblast’s Executive Committee, situated out of the Company’s U.S. headquarters in New Haven, CT.

As previously announced, Udi Gilboa, co-founder of the Company, who until today was the CFO, will now transition to a special advisor role reporting to the Chief Executive Officer (CEO), and will continue as a member of the Company’s board of directors.

Continue reading

  • November 16, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Strengthens Leadership Team and Announces Key Organizational Changes

Significant Evolution of Senior Leadership Team in 2015

Co-Founders Transition Company to Globally-Experienced Executives

NEW HAVEN, Conn., Nov. 16, 2015 (GLOBE NEWSWIRE) — Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced the appointment of three new senior executives to its leadership team: Warren Wasiewski, M.D. as Chief Medical Officer and Vice President, Research & Development, Leigh Cherry as Vice President Manufacturing, and Stacey Jurchison as Vice President, Investor Relations & Corporate Communications. Recently, the company also announced the appointments of Paul Firuta as Chief Commercial Officer, and Theresa (Terri) Stevens as Chief Corporate Development Officer. All are U.S.-based positions with global responsibilities.

Continue reading

  • November 9, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Announces Website Availability of Webcast Related to Key Opinion Leader Meeting in Oculopharyngeal Muscular Dystrophy (OPMD)

NEW HAVEN, Conn., Nov. 9, 2015 (GLOBE NEWSWIRE) — Bioblast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced the availability of a webcast on its website of a Key Opinion Leader Meeting in oculopharyngeal muscular dystrophy (OPMD) that took place on November 6th, 2015 in New York City.

The meeting featured a keynote presentation by internationally-renowned key opinion leader, Bernard Brais, MDCM, MPhil, PhD, FRCP(C), a leading neurologist and Professor of Neurology and Human Genetics at McGill University, Director of the CHUM Ataxia Centre in Montreal, and Co-Director of the Rare Neurological Diseases Group of the Montreal Neurological Institute, one of the leading institutions in this disease area.

Continue reading

Pages